美股市场个股详情
GNMSF GENMAB AS
- 285.910
- -3.834-1.32%
延时15分钟行情交易中 05/06 11:47 (美东)
184.87亿总市值23.87市盈率TTM
296.590最高价285.910最低价143股成交量285.910今开289.744昨收4.22万成交额0.00%换手率30.01市盈率(静)6465.98万总股本424.10052周最高3.96市净率183.00亿流通值262.00052周最低--股息TTM6400.52万流通股500.920历史最高--股息率TTM3.69%振幅260.250历史最低295.453平均价1股每手
关于GENMAB AS公司
Genmab是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术包括DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab合作创建了Darzalex，它被认为是多发性骨髓瘤的标准治疗，是Genmab的主导产品。Genmab还有用于甲状腺眼病的Tepezza（与Horizon合作），用于复发性多发性硬化症的Kesimpta（与诺华合作），Rybrevant（与强生合作）用于非小细胞肺癌（NSCLC），Tivdak（与Seagen合作）用于宫颈癌，Epkinly（与艾伯维合作）用于弥漫性大B细胞淋巴瘤。Genmab有几种针对其他肿瘤适应症的候选药物。
公司介绍
公司代码GNMSF
公司名称GENMAB AS
上市日期2019/07/18
成立日期1998
CEODr. Jan G. J. van de Winkel, PhD
所属市场粉单
员工数量2204
证券类型海外普通股
年结日12-31
公司地址Carl Jacobsens Vej 30,Valby
城市Copenhagen
省份丹麦中部
国家丹麦
邮编2500
电话45-70-20-27-28
董事高管
- 姓名
- 职务
- 年薪
- Dr. Jan G. J. van de Winkel, PhD
- President and Chief Executive Officer
- 4430.00万
- Christopher Cozic
- Executive Vice President and Chief People Officer
- 1320.00万
- Anthony Mancini
- Executive Vice President and Chief Operating Officer
- 2180.00万
- Anthony Pagano
- Executive Vice President and Chief Financial Officer
- 1960.00万
- Dr. Martine J. van Vugt, PhD
- Executive Vice President and Chief Strategy Officer
- 890.00万
- Birgitte Stephensen
- Executive Vice President and Chief Legal Officer
- 1010.00万
- Dr. Tahamtan Ahmadi, PhD
- Executive Vice President, Chief Medical Officer and Head of Experimental Medicines
- 1980.00万
- Dr. Judith Klimovsky
- Executive Vice President and Chief Development Officer
- 2170.00万
- Dr. Mijke Zachariasse
- Director, Vice President and Head of Antibody Research Materials
- 110.00万
- Pernille Erenbjerg
- Deputy Chairman of the Board
- 210.00万
- Deirdre P. Connelly
- Chairman of the Board
- 280.00万
- Martin Schultz
- Director, Senior Director and Head of Development Business Partnership and Strategy
- 80.00万
- Takahiro Hamatani
- Director and Senior Director, Finance Japan
- 80.00万
- Anders Gersel Pedersen, M.D.,PhD
- Director
- 170.00万
- Rolf Karl-Heinz Hoffmann
- Independent Director
- 150.00万
- Dr. Paolo Paoletti, M.D.
- Independent Director
- 150.00万
- Elizabeth G. O’Farrell
- Independent Director
- 190.00万
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅